Korea Investment CORP Takes $22.18 Million Position in Insulet Corporation $PODD

Korea Investment CORP acquired a new position in shares of Insulet Corporation (NASDAQ:PODD) in the 2nd quarter, HoldingsChannel.com reports. The fund acquired 145,651 shares of the medical instruments supplier’s stock, valued at approximately $22,175,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Larson Financial Group LLC raised its stake in Insulet by 114.6% during the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 47 shares in the last quarter. University of Texas Texas AM Investment Management Co. bought a new position in shares of Insulet in the fourth quarter worth $26,000. Elyxium Wealth LLC acquired a new position in shares of Insulet during the fourth quarter valued at $28,000. DV Equities LLC acquired a new position in shares of Insulet during the fourth quarter valued at $28,000. Finally, MV Capital Management Inc. bought a new stake in shares of Insulet during the fourth quarter valued at about $29,000.

Insider Buying and Selling at Insulet

In related news, Director Timothy C. Stonesifer purchased 2,790 shares of the firm’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was acquired at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the transaction, the director directly owned 9,041 shares of the company’s stock, valued at $1,297,473.91. This trade represents a 44.63% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.36% of the stock is owned by company insiders.

Insulet News Summary

Here are the key news stories impacting Insulet this week:

• Neutral Sentiment: Pomerantz said a class action has been filed in the U.S. District Court for the District of Massachusetts under docket 26-cv-13062. The proposed class generally covers investors who purchased Insulet securities between February 21, 2025, and May 26, 2026, and seeks damages under Sections 10(b) and 20(a) of the Securities Exchange Act. Pomerantz class action filing
• Neutral Sentiment: Several law firms—including DJS Law Group, Schall Brown & Schwartz, Robbins Geller, Faruqi & Faruqi, Rosen, Bronstein Gewirtz & Grossman, and Bernstein Liebhard—reminded shareholders of an August 31 deadline to seek appointment as lead plaintiff. These announcements are primarily investor solicitations rather than new operational developments. Robbins Geller investor deadline
• Negative Sentiment: The allegations center on purportedly false or misleading statements about Insulet’s manufacturing quality and product safety. One investor notice linked the claims to two Omnipod medical-device corrections and reported substantial share-price declines following corrective disclosures. If the case advances, Insulet could face litigation expenses, potential damages, reputational harm, and additional scrutiny of its products and disclosures. Insulet shareholder lawsuit allegations

Insulet Price Performance

PODD stock opened at $148.16 on Monday. The firm has a market cap of $10.27 billion, a PE ratio of 27.69, a P/E/G ratio of 1.17 and a beta of 1.10. Insulet Corporation has a 12 month low of $126.40 and a 12 month high of $354.88. The firm has a 50 day simple moving average of $154.67 and a 200 day simple moving average of $184.30. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.83.

Insulet (NASDAQ:PODD) last issued its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.47 by $0.19. The business had revenue of $801.70 million for the quarter, compared to analysts’ expectations of $787.39 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The company’s quarterly revenue was up 23.5% on a year-over-year basis. During the same period in the previous year, the firm posted $1.17 EPS. Insulet has set its FY 2026 guidance at 6.460- EPS. Equities research analysts forecast that Insulet Corporation will post 6.51 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Citigroup raised their target price on shares of Insulet from $165.00 to $172.00 and gave the company a “neutral” rating in a research note on Wednesday, July 8th. UBS Group dropped their target price on Insulet from $174.00 to $150.00 and set a “neutral” rating on the stock in a report on Thursday, August 6th. Barclays cut their target price on Insulet from $286.00 to $198.00 and set an “underweight” rating for the company in a research report on Thursday, May 7th. Canaccord Genuity Group decreased their price target on Insulet from $249.00 to $179.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Finally, BTIG Research cut Insulet from a “buy” rating to a “neutral” rating in a research report on Thursday, August 6th. Fourteen investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $195.40.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.